Venetoclax (VCT/ABT-199) is the first highly selective oral BCL-2 antagonist licensed by the FDA for the treatment of relapsed/refractory chronic lymphocytic leukemia (CLL) with 17p deletion (18) and for patients age 75 and older with newly diagnosed AML or who have complications that made intensive induction chemotherapy ineligible. This evidence concerns the gene BCL2 and acute myeloid leukemia.